Patents by Inventor Vishweshwaraiah Baligar

Vishweshwaraiah Baligar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OXOPYRROLIDINE FPR2 AGONISTS
    Publication number: 20230348426
    Abstract: The disclosure relates to compounds of Formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: July 8, 2021
    Publication date: November 2, 2023
    Inventors: Pravin Sudhakar Shirude, Chandrasekhar Reddy Rachamreddy, Amit Kumar Chattopadhyay, Balaji Seshadri, Vishweshwaraiah Baligar, Sudhakara Reddy Madduri, Ellen K. Kick, Nicholas R. Wurtz
  • OXOPYRROLIDINE UREA FPR2 AGONISTS
    Publication number: 20230303513
    Abstract: The disclosure relates to compounds of Formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: August 11, 2021
    Publication date: September 28, 2023
    Inventors: Pravin Sudhakar Shirude, Chandrasekhar Reddy Rachamreddy, Vishweshwaraiah Baligar, Balaji Seshadri, Sudhakara Reddy Madduri, Ellen K. Kick, Nicholas R. Wurtz
  • Phenylpyrrolidinone formyl peptide 2 receptor agonists
    Patent number: 11708327
    Abstract: The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: July 25, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Pravin Sudhakar Shirude, Vishweshwaraiah Baligar, Balaji Seshadri, Amit Kumar Chattopadhyay, Nicholas R. Wurtz, Ellen K. Kick
  • PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS
    Publication number: 20210371378
    Abstract: The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: August 12, 2021
    Publication date: December 2, 2021
    Inventors: Pravin Sudhakar Shirude, Vishweshwaraiah Baligar, Balaji Seshadri, Amit Kumar Chattopadhyay, Nicholas R. Wurtz, Ellen K. Kick
  • Phenylpyrrolidinone formyl peptide 2 receptor agonists
    Patent number: 11117861
    Abstract: The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: September 14, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Pravin Sudhakar Shirude, Vishweshwaraiah Baligar, Balaji Seshadri, Amit Kumar Chattopadhyay, Nicholas R. Wurtz, Ellen K. Kick
  • PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS
    Publication number: 20200255375
    Abstract: The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: April 24, 2020
    Publication date: August 13, 2020
    Inventors: Pravin Sudhakar Shirude, Vishweshwaraiah Baligar, Balaji Seshadri, Amit Kumar Chattopadhyay, Nicholas R. Wurtz, Ellen K. Kick
  • Phenylpyrrolidinone formyl peptide 2 receptor agonists
    Patent number: 10676431
    Abstract: The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: June 9, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Pravin Sudhakar Shirude, Vishweshwaraiah Baligar, Balaji Seshadri, Amit Kumar Chattopadhyay, Nicholas R. Wurtz, Ellen K. Kick
  • PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS
    Publication number: 20190270704
    Abstract: The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: March 4, 2019
    Publication date: September 5, 2019
    Inventors: Pravin Sudhakar Shirude, Vishweshwaraiah Baligar, Balaji Seshadri, Amit Kumar Chattopadhyay, Nicholas R. Wurtz, Ellen K. Kick
  • TGF BETA RECEPTOR ANTAGONISTS
    Publication number: 20180250303
    Abstract: The invention relates generally to compounds of formula (I) that modulate the activity of TGF?R-1 and TGF?R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    Type: Application
    Filed: August 23, 2016
    Publication date: September 6, 2018
    Inventors: Robert M. Borzilleri, Brian E. Fink, Lalgudi S. Harikrishnan, Upender Velaparthi, Vishweshwaraiah Baligar, Hasibur Rahaman, Jayakumar Sankara Warrier